title: Systemic bioactivity of intranasal triamcinolone and mometasone in perennial allergic rhinitis.
abstract: OBJECTIVE
  To evaluate the systemic bioactivity of triamcinolone acetonide (TA) 220 micro g or mometasone furoate (MF) 200 micro g over 3 weeks in perennial allergic rhinitis.
  
  
  METHODS
  Twenty-seven patients received TA 220 micro g or MF 200 micro g once daily for 3 weeks with a 2 week placebo washout period prior to each randomized treatment. Measurements were made at baseline after each washout and after each randomized treatment, comprising overnight 10-h urinary cortisol corrected for creatinine (OUCC), 08.00 h plasma cortisol and 08.00 h serum osteocalcin.
  
  
  RESULTS
  There were no significant differences between baseline values prior to TA or MF, and for any outcome measures comparing randomized treatments to respective baseline values or comparing TA with MF. For OUCC compared with baseline, the geometric mean fold suppression (95% CI) was 1.02 (0.78, 1.33) for TA (2% decrease), 1.07 (0.80, 1.42) for MF (7% decrease), and 1.05 (0.79, 1.39) for TA vs MF (5% decrease).
  
  
  CONCLUSIONS
  Standard doses of TA or MF over 3 weeks showed no differences in systemic bioactivity markers compared with respective baseline values after placebo washout, and there were no differences between TA vs MF.
authors.affiliation: Asthma & Allergy Research Group, Department of Clinical Pharmacology & Therapeutics, Ninewells Hospital & Medical School, University of Dundee, Dundee DD1 9SY, Scotland, UK.
authors.forename: Daniel K C
authors.initials: DK
authors.lastname: Lee
authors.forename: Fiona M
authors.initials: FM
authors.lastname: Robb
authors.forename: Erika J
authors.initials: EJ
authors.lastname: Sims
authors.forename: Graeme P
authors.initials: GP
authors.lastname: Currie
authors.forename: Lesley C
authors.initials: LC
authors.lastname: McFarlane
authors.forename: Brian J
authors.initials: BJ
authors.lastname: Lipworth
mesh_terms: D000281:Administration, Intranasal; D000328:Adult; D004341:Drug Evaluation; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000493:pharmacokinetics; D006801:Humans; D008297:Male; D000068656:Mometasone Furoate; D011244:Pregnadienediols / Q000008:administration & dosage* / Q000493:pharmacokinetics; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*; D014221:Triamcinolone / Q000008:administration & dosage* / Q000493:pharmacokinetics
chemical_list: D005938:Glucocorticoids; D011244:Pregnadienediols; D000068656:Mometasone Furoate; D014221:Triamcinolone